Robert Wozniak, MD
Endocrinology, Diabetes & Metabolism · Rock Hill, SCNPI 1942282470
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 757 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations.
Across 757 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Sanofi-aventis U.S. LLC$1K
- Abbott$1K
- Mannkind Corporation$866
- Novo Nordisk$739
- Corcept Therapeutics$720
- plus $8K from 54 others
What the payments were for
- Food & beverage$14,42399%
- Education$901%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$377
- FibroScan$293
- Ozempic$250
- PROCLAIM$159
- Inspire$139
- AFREZZA$125
- Kerendia$123
- CeQur Simplicity$121
- FREESTYLE LIBRE 3$114
- TEPEZZA$106
- MYCAPSSA$101
- JARDIANCE$100
How this compares
$14,572 in reported general payments places this provider in the 80th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 11 | $443,736 |
| OzempicSemaglutide | 202 | $315,593 |
| JardianceEmpagliflozin | 160 | $174,707 |
| TrulicityDulaglutide | 77 | $126,822 |
| MounjaroTirzepatide | 85 | $120,432 |
| FarxigaDapagliflozin Propanediol | 115 | $102,532 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 18 | $55,978 |
| Tresiba Flextouch U-100Insulin Degludec | 56 | $46,896 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $37,810 |
| AfrezzaInsulin Regular, Human | 15 | $33,080 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 32 | $31,587 |
| Humalog Kwikpen U-100Insulin Lispro | 98 | $30,768 |
| RybelsusSemaglutide | 28 | $27,825 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $19,855 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 118 | $19,851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $720 | $443,73611 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $739 | $346,375241 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,773 | $247,254162 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $567 | $201,687194 claims |
| AstraZenecaFarxiga | $657 | $102,532115 claims |
| Mannkind CorporationAfrezza | $866 | $33,08015 claims |
| MerckJanuvia | $377 | $17,73322 claims |
| BayerKerendia | $506 | $17,03225 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,281 | $12,04311 claims |
| Acerus Pharmaceuticals CorporationNatesto | $34 | $10,05418 claims |
| AbbVieSynthroid | $188 | $9,314100 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $453 | $3,667401 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Rock Hill
- Gauri DhirMyrtle Beach$417K
- Cory WhiteGreenville$413K
- Louis HaenelCharleston$377K
- Vonda CalcuttWalterboro$368K
- Ray VaughtersAiken$321K
- Donald EagertonMyrtle Beach$284K
- Beatrice HullCharleston$214K
- Joseph MathewsSummerville$168K
- Brittany HendersonMount Pleasant$157K
- Zouhair BibiConway$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.